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13 February 2013 
Dear Minister,  
 
Re: Definition of cannabis based medicine 
 
I write further to my correspondence to James Brokenshire MP of 17 January 2011 
in relation to the advice on the cannabis based medicine Sativex.  In my previous 
correspondence, the Advisory Council on Misuse of Drugs (ACMD) reaffirmed its 
advice from 2003 that Sativex should be placed in Schedule 4 under the Misuse of 
Drugs Regulations 2001 (as amended).  The ACMD further concluded that Sativex 
has a low abuse potential and low risk of diversion and therefore Schedule 4, Part 1 
would be the most appropriate scheduling provision.   
 
In October 2012 the Home Office presented to the ACMD a revised definition of 
cannabis based medicines, such as Sativex, under the Misuse of Drugs Regulations 
2001. The ACMD gave detailed consideration to the the options and concludes that 
the most appropriate definition is:  
 
 
“A liquid formulation– 
 
(a) containing a botanical extract of Cannabis – 
(i) with a concentration of not more than 30 milligrammes of 
cannabidiol per millilitre, and not more than 30 
milligrammes of delta-9-tetrahydrocannabinol per millilitre, 
and  
(ii) where the ratio of cannabidiol to delta-9-
tetrahydrocannabinol is between 0.7 and 1.3  
  
(b) which is dispensed through a metered dose pump as a mucosal mouth 
spray and  
 
which was approved for marketing by the Medicines and Healthcare Products 
Regulatory Agency (MHRA)” 
  
As Sativex has a low abuse potential and low risk of diversion, the ACMD also 
advises that it is not appropriate to apply Regulation 27 of the Misuse of Drugs 
Regulations 2001. The ACMD does not consider the witnessing requirements set out 
in Regulation 27 necessary for Sativex.  
 
The ACMD is conscious of the UK’s obligations under the United Nations Single 
Convention on Narcotic Drugs 1961. The ACMD is satisfied with the proposal to 
expand Regulation 22  to include a new sub paragraph (5) requiring anyone who 
acquires or disposes of drugs in Schedule 3 and 4 (including Sativex) to keep 
records of such acquisition or disposal.  These measures will ensure that UK 
complies with its international obligations under the UN Single Convention on 
Narcotic Drugs 1961 (Article 34 (b)).   
 
It is important to make clear that the ACMD considers that cannabis based 
medicines (as tightly defined above) are distinct from herbal cannabis. The definition 
above delineates cannabis based medicines, where the active ingredients are 
specific and tightly controlled, from herbal cannabis, which remains a Schedule 1 
drug.  
 
Yours sincerely, 
 
 
 
 
Professor Les Iversen FRS CBE 
 
 
Cc: Anna Soubry, Parliamentary Under Secretary of State for Health  
 
 
